Testing A New Experimental Drug To Raise Good Cholesterol Level

Testing A New Experimental Drug To Raise Good Cholesterol Level.
An theoretical poison that raises HDL, or "good," cholesterol seems to have passed an primary block by proving safe in preliminary trials. Although the provisional was primarily designed to look at safety, researchers scheduled to gift the finding Wednesday at the American Heart Association's annual joining in Chicago also report that anacetrapib raised HDL cholesterol by 138 percent and eschew LDL, HDL's infelicitous twin, almost in half arab xnxx. "We saw very encouraging reductions in clinical events," said Dr Christopher Cannon, clue maker of the study, which also appears in the Nov 18, 2010 progeny of the New England Journal of Medicine.

A big study to support the results would take four to five years to complete so the numb is still years away from market who is a cardiologist with Brigham and Women's Hospital in Boston. Other experts are intrigued by the findings, but note that the dig into is still in very inopportune stages. "There are a lot of people in the prevention/lipid field that are simultaneously agitated and leery," said Dr Howard Weintraub, clinical principal of the Center for the Prevention of Cardiovascular Disease at NYU Langone Medical Center in New York City.

Added Dr John C LaRosa, president of the State University of New York (SUNY) Downstate Medical Center in New York City: "It's very prelude but it's impressive because the carry on psychedelic out of the barrel of this variety was not a success. This looks like a better drug, but it's not ultimate by any means. Don't take this to the bank".

LaRosa was referring to torcetrapib, which, in the manner of anacetrapib, belongs to the category of drugs known as cholesterol ester transfer protein (CETP) inhibitors. A gargantuan trial on torcetrapib was killed after investigators found an increased peril of death and other cardiovascular outcomes. "I would be more frenetic about anacetrapib if I hadn't seen what happened to its cousin torcetrapib. Torcetrapib raised HDL astoundingly but that was in all respects neutralized by the enlarge in cardiovascular events".